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Aims Natriuretic peptide-guided (NP-guided) treatment of heart failure has been tested against standard clinically guided care
in multiple studies, but findings have been limited by study size. We sought to perform an individual patient data meta-
analysis to evaluate the effect of NP-guided treatment of heart failure on all-cause mortality.
Methods
and results
Eligible randomizedclinical trialswere identified fromsearchesofMedline andEMBASEdatabases and theCochraneClin-
ical Trials Register. The primary pre-specified outcome, all-cause mortality was tested using a Cox proportional hazards
regressionmodel that included study of origin, age (,75 or ≥75 years), and left ventricular ejection fraction (LVEF,≤45
or .45%) as covariates. Secondary endpoints included heart failure or cardiovascular hospitalization. Of 11 eligible
studies, 9 provided individual patient data and 2 aggregate data. For the primary endpoint individual data from 2000
patients were included, 994 randomized to clinically guided care and 1006 to NP-guided care. All-cause mortality was
significantly reduced by NP-guided treatment [hazard ratio ¼ 0.62 (0.45–0.86); P ¼ 0.004] with no heterogeneity
between studies or interaction with LVEF. The survival benefit from NP-guided therapy was seen in younger (,75
years) patients [0.62 (0.45–0.85); P ¼ 0.004] but not older (≥75 years) patients [0.98 (0.75–1.27); P ¼ 0.96]. Hospital-
ization due to heart failure [0.80 (0.67–0.94); P ¼ 0.009] or cardiovascular disease [0.82 (0.67–0.99); P ¼ 0.048]was sig-
nificantly lower in NP-guided patients with no heterogeneity between studies and no interaction with age or LVEF.
Conclusion Natriuretic peptide-guided treatment of heart failure reduces all-cause mortality in patients aged,75 years and overall
reduces heart failure and cardiovascular hospitalization.
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Introduction
How best to guide the complex pharmacotherapy of chronic heart
failure is in dispute. Whereas some medications, namely angiotensin
converting enzyme inhibitors (ACEi), angiotensin receptor antago-
nists, certain beta-blockers (BB), and mineralocorticoid receptor
antagonists (MRA) have been shown to improve survival in patients
with chronic heart failure and a reduced left ventricular ejection frac-
tion (LVEF),1 the optimal dosage of these agents in individuals is
guided largely by subjective indices, namely the clinician’s assessment
of symptoms, bedside signs and tolerability. Consequently, evidence-
based target doses of these proven medications are rarely achieved
outside the clinical trial setting, even in eligible patients.2 Despite
lack of trial evidence for longevity benefit, loop and/or thiazide-like
diuretics are seen as central to the treatment of almost all patients
with chronic heart failure.Here again, optimal or target doses aredic-
tated largely by clinician interpretation of the patient’s symptoms and
signs. Itwouldobviously be useful if pharmacotherapy could bedirec-
ted not only by subjective bedside indices but also by an objective
index of circulatory status. In this regard, it has been proposed that
circulating levels of the B-type cardiac natriuretic peptides (BNP
and NT-proBNP), which are released from the heart in proportion
to stretch of the cardiac chambers, might provide such an objective
guide. This proposition is reinforced first, by evidence that circulating
levels of these peptides and change in their levels over time provide a
robust prognostic index in chronic heart failure3 and second, each of
the drug groups which demonstrably increase longevity, as well as
loop diuretics, reduce their levels in the circulation.4
Several studies have addressed the hypothesis, first proposed in
the late 1990s, that pharmacotherapy guided by BNPorNT-proBNP
levels (NP-guided treatment) would improve clinical outcomes.5–15
While some of these studies demonstrated a reduction in combined
clinical events, no single study was adequately powered to test the
effect of this strategy on all-cause mortality—the ultimate clinically
relevant endpoint.
In viewing results from published studies, the European Society of
Cardiology,1 theNational Institute forHealth andClinical Excellence
(NICE),16 the American College of Cardiology/American Heart As-
sociation,17 the National Academy of Clinical Biochemistry,18 and
the National Heart Foundation of Australia and Cardiac Society of
Australia and New Zealand19 opined that the evidence is insufficient
to support routine NP-guided treatment over conventional care.
Previous literature-basedmeta-analyses using aggregate data have
suggested that NP-guided treatment may be associated with a 20–
30% reduction in all-cause mortality.20–22 Such meta-analyses,
however, can have important limitations relating to potential hetero-
geneity of patient characteristics and outcome definitions. In con-
trast, meta-analyses based on individual patient data allow more
rigorous testing with the incorporation of standard outcome defini-
tions and provide the opportunity to consider important patient
characteristics that could influence outcomes or mitigate/moderate
the effects of treatment interventions on outcomes.23 Accordingly,
we performed an individual patient data meta-analysis, which
includes data from studies published subsequent to two of the
earlier aggregate data meta-analyses7,12,13 to test the hypothesis
that compared with conventional clinically guided management,
NP-guided therapy results in a reduction in all-cause mortality.
Methods
Search strategy and selection criteria
We searched MEDLINE and EMBASE for studies published between 1
January 2000 and 29 February 2012. The search query included key-
words and correspondingMeSH terms for natriuretic peptide, brain natri-
uretic peptide, B-type natriuretic peptide, N-terminal pro-brain natriuretic
peptide, heart failure, treatment, and therapy. Similar searches were
made of the Cochrane Controlled Clinical Trials Register database
andof the clinicaltrials.govwebsite.Only randomized controlled clinical
trials reporting all-cause mortality and comparing B-type natriuretic
peptide-guided treatment of heart failure with clinically guided treat-
mentwere included. Theexceptionwasone studywhich,while not pro-
viding all-cause mortality data, was randomized and provided robust
secondary endpoint results.13 The search strategy was similar to that
described in publications reporting meta-analyses based on aggregate
data.20 – 22
Data extraction
Individual patient data from eligible studies were entered into the
meta-analysis database and included patient age, gender, baseline
BNP or NT-proBNP level (pg/mL), baseline creatinine (mmol/L), base-
line LVEF (%), treatment assignment (NP-guided or clinically guided),
and randomization date. Outcome data included all-cause mortality
and date of all-cause death or last follow-up. First hospitalization for
any cause, for heart failure or for any cardiovascular disease, along
with the date of hospitalization was also included. Only events occur-
ring during application of the treatment strategy were included in the
analysis.
Statistical analysis
The pre-specified primary outcome was all-cause mortality. Secondary
outcomes included death or any hospitalization, cardiovascular hospital-
ization, heart-failure hospitalization, and all-cause hospitalization.
We analysed all outcomes as time-to-event data using Cox propor-
tional hazards regression models. The time-to-event data include
follow-up as reported in the publications from each study and therefore
does not extend beyond the period of the guided treatment in each
study. Age (,75, ≥75 years), LVEF (≤45%, .45%) at enrolment,
study (as a fixed effect), treatment allocation (NP-guided vs. clinically
guided), treatment*age, treatment* LVEF, and treatment*study were
included as terms in the regression models. The interaction terms
(treatment*age and treatment* LVEF) were used to test the consist-
ency of treatment effects across age and LVEF groups. We used the
treatment*study interaction effect to test the heterogeneity of treat-
ment effects across studies. The impact of study geographical location
on treatment strategy and medication changes was tested by adding
geographical location (Europe, USA, or New Zealand) as a covariate
within the Cox model.
Hazard ratios comparing outcomes in the NP-guided and clinically
guided treatment groups were summarized for all studies pooled and
for each study individually with 95% confidence intervals. Kaplan–
Meier curves were used to portray the comparative time to event
results.
We compared changes inmedications, plasma natriuretic peptide, and
creatinine levels between groups using general linear models. These
models included age, LVEF, study, and treatment as factors.
Weperformed all individual patient analyseswith SPSS (v19) software.
Analyses using aggregated measures and production of the associated
forest plots were undertaken with RevMan5.
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Results
We identified 11 eligible studies (Figure 1, Table 1),5–15 8 of which
provided individual patient data for all-cause mortality (n ¼
2000).5–12 Based on excellent concordance between data provided
for themeta-analysis and the original published reports, the quality of
data was judged to be high. All studies reported endpoints on an
intention-to-treat basis. For two studies, data from only two treat-
ment groups (NP-guided and clinically guided) who received inten-
sive clinical follow-up were considered for the analysis, whereas
data from the third (‘usual care’) groups were not included.7,10 For
two studies, complete individual patient data were not available but
aggregate data on overall mortality were obtained from published
reports (n ¼ 2431 when aggregate data included).14,15 Finally, the
ProBNP Outpatient Tailored Chronic Heart Failure Therapy
(PROTECT) trial, while not providing overall mortality data, gave
robust secondary endpoint results (n ¼ 2151 for individual patients
with data for secondary end-points).13
Study characteristics
There were differences between studies regarding design relating to
duration, target plasma level for the B-type natriuretic peptides, and
treatment algorithm (Table 1), but all studies compared a treatment
strategy guidedbyBNP/NT-proBNPwith clinically guided treatment.
Themajority of studies used a single target BNPorNT-proBNP level
for the NP-guided group. In two studies, age-stratified NT-proBNP
targets were utilized.6,12 In one study, a target of ≥50% reduction
in NT-proBNP was used9 and in a further two studies an individua-
lized BNP or NT-proBNP target was utilized based on levels at dis-
charge from hospital.8,11 Treatment algorithms differed slightly
between studies, but were all based upon stepwise up-titration of
guideline-recommended drug therapies.
Patient characteristics
Patient characteristics for themeta-analysis cohort and for individual
studies are summarized inTable2. The average ageofparticipantswas
72 years and two-thirds were male. The majority of subjects had LV
systolic dysfunction and only 10% had an LVEF .45%.
Primary endpoint
During active treatment, there were 207 deaths among patients
assigned to clinically guided treatment compared with 172 deaths
in the NP-guided group [HR ¼ 0.62 (CI 0.45–0.86); P ¼ 0.004,
Figure 2]. There was no significant heterogeneity in the effect of
NP-guided therapy on all-cause mortality between studies (P ¼
0.57, Cox interaction term). There was, however, a significant inter-
action between age and treatment efficacy (P ¼ 0.028), with a sur-
vival benefit for NP-guided vs. clinical treatment in patients aged
,75 years [HR ¼ 0.62 (0.45–0.85); P ¼ 0.004] but not in patients
≥75 years [HR ¼ 0.98 (0.75–1.3); P ¼ 0.96, Figure 2].No interaction
was evident for LVEF. There was no significant interaction between
geographical location and treatment efficacy for the primary end-
point of all-cause mortality (P ¼ 0.8 for interaction term) or any
other endpoint (P ≥ 0.6 for all).
Combining the eight studies providing individual patient data with
the two studies reporting aggregated data using a random effects
model demonstrated a significant (P ¼ 0.045) reduction in all-cause
mortality with NP-guided therapy (unadjusted, Figure 3). There was
no significant heterogeneity exhibited between studies.
Secondary endpoints
Heart failure hospitalizations were reduced in the NP-guided group,
n ¼ 247 compared with n ¼ 294 in clinically guided patients [HR ¼
0.80 (0.67–0.94); P ¼ 0.009] as were cardiovascular admissions
[n ¼ 430 in the NP-guided group compared with n ¼ 448, HR ¼
0.82 (0.67–0.99); P ¼ 0.048] with no heterogeneity between
studies and no interaction with age or LVEF. When combined with
aggregate data from two additional studies, a significant reduction
in HF hospitalization was observed (unadjusted, Figure 4). All-cause
hospitalization [HR ¼ 0.94 (0.84–1.07); P ¼ 0.38] was not reduced
by NP-guided treatment (n ¼ 555 NP-guided, n ¼ 560 clinically
guided); however, the combined endpoint of all-cause mortality
or all-cause hospitalization was lower for NP-guided treatment
(n ¼ 587) compared with clinically guided therapy (n ¼ 605)
[HR ¼ 0.84 (0.71–0.99); P ¼ 0.037].
Effects on natriuretic peptide levels
Follow-up plasma NT proBNP levels were available in 1313 partici-
pants at the end of the study (NP-guided group 668, clinically
guided group 645). Among these subjects, there was a similar fall in
NT-proBNP levels in the former [35.0% (28.5–41.0)] and latter
groups [31.5% (24.5–37.8); P ¼ 0.44]. The fall in NT-proBNP was
significantly (P, 0.001) greater for patients aged ,75 years. There
was, however, no interaction between age and treatment effect
(P ¼ 0.38), with comparable differences in the fall in NT-proBNP
between treatment groups in the younger [NP-guided group 43.4%
(34.8–50.9), clinical group 40.8% (31.2–49.0); P ¼ 0.67] and older
Figure 1 Flow diagram outlining search strategy, study selection,
and reasons for exclusion.
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Table 1 Study characteristics
Peptide target Clinical
target
Primary endpoint Study
period
Duration Follow-up Treatment algorithm
Studies providing individual patient data
Christchurch Pilot5 NT-proBNP,1700 pg/mL HF score Mortality + CV
hospitalization + out-patient HF
1997–99 9.5 months 2-weekly until targetmet,
then 3-monthly
Stepwise increase in ACEi,
diuretic, AA, additional
vasodilator
TIME-CHF6 NT-proBNP,400a;
NT-proBNP,800b
NYHA ≤II Survival free of hospitalization 2001–06 18 months 1, 3, 6, 12, 18 months Investigator determined
stepwise increase in therapy
via algorithm
Vienna7 NT-proBNP,2200 pg/mL Clinical
assessment
Survival without HF hospitalization 2003–04 ≥12
months
2-weekly to meet target,
1, 3, 6, and 12 months
Investigator determined increase
in therapy
PRIMA8 Individual: lowest NT-proBNP
at discharge or at 2-week
follow-up
Clinical
assessment
Days alive and out of hospital 2004–07 ≥12
months
2 and 4 weeks, then 3
monthly
Investigator determined increase
in guideline based therapy
SIGNAL-HF9 NT-proBNP reduction .50%
from baseline
Clinical
assessment
Composite of days alive, days out of
hospital and symptom score
2006–09 9 months 1, 3, 6, and 9 months Investigator determined
stepwise increase in
guideline-based therapy
BATTLESCARRED10 NT-proBNP,1300 pg/mL HF score All-cause mortality 2001–06 24 months 2-weekly until targetmet,
then 3-monthly
Stepwise increase in ACEi, BB,
diuretic, AA, additional
vasodilator
STARBRITE11 Individual BNP at discharge Congestion
score
Days alive and out of hospital 2003–05 .3
months
10, 30, 60, 90, 120 days
and additional visits as
required
Investigator determined increase
in therapy
UPSTEP12 BNP,150 ng/La; BNP
,300 ng/Lb
Clinical
assessment
Composite of all-cause mortality,
hospitalization, or HF worsening
2006–09 ≥12
months
Weeks 2, 6, 10, 16, 24, 36,
48, then 6-monthly
Investigator determined
stepwise increase in therapy
via algorithm
PROTECTc13 NT-proBNP,1000 pg/mL Clinical
assessment
Total cardiovascular events 2006–10 ≥6
months
As required to achieve
target then 3-monthly
Investigator determined increase
in guideline based therapy
Studies providing aggregate data
STARS-BNP14 BNP, 100 pg/mL Clinical
assessment
HF mortality + HF hospitalization 2001–05 15 months Months 1, 2, 3 and then
3-monthly
Investigator determined increase
in guideline based therapy
Anguita et al .15 BNP, 100 pg/mL Clinical Score Survival free of HF hospitalization 16 months 1, 2, 3, 6, 12, and 18
months
Investigator determined increase
in guideline-based therapy
HF, heart failure; CV, cardiovascular; ACEi, angiotensin-converting enzyme inhibitor; BB, beta-blocker; AA, aldosterone antagonist; NYHA, New York Heart Association functional class.
aPatients aged ,75 years.
bPatients aged ≥75 years.
cThe PROTECT study provided only secondary endpoint data.
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age groups [NP-guided group 26.4% (15.3–36.0), clinical 19.9%
(8.8–29.7); P ¼ 0.38].
Plasma creatinine levels, available in 1396 patients at the end
of the study (713 patients in the NP-guided group and 683 in
the clinical group), showed a tendency to rise similarly in both
groups (+12.6+1.9 mmol/L and +12.7+1.9 mmol/L, respective-
ly, P ¼ 0.98).
Medication changes
The percentage of patients receiving medications recommended by
heart failure guidelines was very high and similar to percentages
reported in large randomized controlled trials performed during
the same time period. Among NP-guided patients, ACEi/ARB, BB,
andMRAwereprescribed in 91, 78, and 29%, respectively, compared
with 89, 73, and 29% in clinically guided patients. Loop diuretics were
prescribed in 87% of patients in both treatment groups. Baseline
doses of medications and the percent of patients receiving target
doses as defined by guidelines were similar in both treatment
groups (Table 3). By the time of last follow-up ACEi/ARB dosing
had increased in the NP-guided group [+8.4% (3.4–13.5) enalapril
equivalents] but changed little in the clinical group [21.2% (26.1–
3.7)] (P ¼ 0.007 for groupcomparison). Therewas a strong age inter-
action with change in ACEi/ARB drug doses which increased among
younger patients (,75 years) in both treatment groups [+11.7%
(5.3–18.0) in the NP-guided group and +4.3% (22.3–10.8) in the
clinical group, P, 0.01], whereas in older patients (≥75 years),
ACEi/ARB doses increased in the NP-guided group by +5.2%
[21.8–12.2] but tended to fall in the clinical group 26.7%
[213.4–0.5], (P, 0.01), (P ¼ 0.006 for age comparison).
Doses of BB had increased to a similar extent in both treatment
groups by the end of follow-up [+12.6% (8.7–16.5) metoprolol
equivalents in the NP-guided group and +13.4% (9.6–17.3) in the
clinical group]. There were, however, significantly greater increases
in younger (,75 years) patients [+16.1% (11.2–21.0) in the
NP-guided group, and+15.0% (9.9–20.0) in the clinical group] com-
pared with older (≥75 years) patients [+9.1% (3.7–14.4) in
NP-guided and +11.9% (6.6–17.1) in the clinical group 26.7%
(213.4–0.5)] (P ¼ 0.037 for age comparison).
Beta-blocker doses as a percent of target were slightly higher at
baseline in the NP-guided compared with clinical groups in the
studies from Europe (43 vs. 35%, respectively, compared with 31
vs. 30% in the USA and 15 vs. 14% in New Zealand; P ¼ 0.044 for
interaction). Lower BB doses in the NZ studies were largely due to
the pilot study,5 which commenced before BB therapywas endorsed
in guidelines. There were no other significant interactions between
geographical study location and medication doses at baseline or
final follow-up.
Inclusion of change in ACEi/ARB dose, change in BB dose, and
change in MRA dose demonstrated that increasing doses of each of
these medications was significantly (P, 0.001 for each) associated
with reduced all-cause mortality. When baseline medication doses
and the change in medication doses during follow-up were included
as co-variates in the Cox regression model, both the NP-guided
treatment strategy and the age by treatment group interaction
remained significant predictors of all-cause mortality [HR for
overall effect ¼ 0.64 (0.46–0.89); P ¼ 0.008]. There was no signifi-
cant interaction between treatment strategy and change in ACEi/
ARB dose (P ¼ 0.7), change in BB dose (P ¼ 0.24), and change in
MRA dose (P ¼ 0.7), indicating that there was no differential effect
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Table 2 Patient characteristics
Number
(BNP-guided
/clinical)
Age (years)
(mean+ SD)
(% >75 years)
Gender
(M/F)
LVEF (%)
(mean+ SD)
(% ≤0.45)
Creatinine
(mmol/L)
(mean+ SD)
NT-proBNP (pg/
mL) [median
(IQR)]
BNP (pg/mL)
(mean+ SD)
Individual patient data
Christchurch Pilot5 33/36 70+10 (35) 53/16 27+8 (100) 100+30 1980 (1077–2806) –
TIME-CHF6 251/248 76+8 (58) 327/172 30+8 (100) 117+38 4194 (2270–7414) –
Vienna7 92/96 71+12 (47) 147/76 29+9 (94) 125+49 2280 (1255–5192) –
PRIMA8 174/171 72+12 (48) 199/146 36+14 (73) 138+58 2949 (1318–5445) –
SIGNAL-HF9 127/125 78+7 (73) 180/72 32+8 (98) 102+38 2362 (1372–4039) –
BATTLESCARRED10 121/121 74+9 (57) 157/85 39+15 (63) 119+45 2001 (1235–2974) –
STARBRITE11 68/69 60+16 (18) 95/42 20+6 (100)a 131+57 – 134 (54–346)
UPSTEP12 140/128 71+10 (39) 196/72 – 108+34 – 608 (356–947)
PROTECT13b 75/76 63+14 (25) 127/24 27+9 (100) 130+40 2118 (1121–3830) –
TOTAL 1081/1070 72+11 (49) 1459/692 31+12 (91) 120+46 2697 (1425–5110) 446 (208–821)
Aggregate data
STARS-BNP14 110/110 66+5 127/93 31+8 95+40 – 352+260c
Anguita et al.15 30/30 70+10 41/19 – – – 136+149
LVEF, left ventricular ejection fraction.
aIndividual LVEF data dichotomized as ,30 or 30–45%.
bThe PROTECT study provided only secondary endpoint data.
cIn the STARS-BNP study, plasma BNP levels available only in the BNP guided arm.
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of medications dependent on treatment strategy such that in both
treatment groups an increase in medications was associated with
improved outcomes.
There was a significant age effect on the change in loop diuretic
dosing (furosemide equivalents) across the study with the dose in-
creasing in younger patients [+13 mg (0.7–25) in the NP-guided
group and +6.4 mg (26.1–19.0) in clinical group] but not in the
older patients [20.6 mg (213.9–12.8) and 27.1 mg (220.1–
5.9)], respectively; (P ¼ 0.027 for age comparison).
Discussion
The hypothesis that circulating levels of the B-type natriuretic
peptides, by providing an objective index of circulatory status in
patients with chronic heart failure, should allow clinicians to more
accurately target pharmacotherapy to the individual patient has intui-
tive appeal. Based on evidence from individual studies and aggregate
data meta-analyses, however, advice to clinicians from specialty soci-
eties regarding the use of BNP-guided management remains cau-
tious,1,16–19 with none proposing that the approach should be
used as a routine. The results of the study reported here should,
we believe, lead to reconsideration of these recommendations.
In our meta-analysis, we used individual patient data from studies
included in and subsequent to those utilized in the earlier
meta-analyses. There were 2000 patients randomized to NP-guided
or clinically guided treatment among whom 379 deaths were
recorded, 172 in those randomized to NP-guidance vs. 207 in the
clinically guided group. There was no significant heterogeneity
across the studies. Furthermore, no interaction with LVEF was
observed although, since only 10% of patients included in this
meta-analysis had a LVEF .45%, such an interaction may possibly
have been seen had a substantial number of patients with heart
failure and preserved left ventricular systolic function been included.
We did, however, observe a significant interaction with age, the all-
cause mortality benefit being seen in patients ,75 years but not in
those aged ≥75 years. One explanation for the lack of mortality
benefit in the older cohort could be that increases in the dose of
some drugs were less overall than in,75 year old patients. It is con-
ceivable, based on results from the PROTECT study,13,24 that elderly
patients will exhibit benefit with more gradual, careful up-titration of
medications according to BNP/NT-proBNP levels than younger
patients. The value of performing an individual patient data
meta-analysis is highlighted by comparing the powerful effect esti-
mate for the NP-guided strategy demonstrated in Figure 2A, where
there is adjustment for key patient characteristics, with the more
modest effect and nominal significance shown in Figure 3, based on
unadjusted aggregate data.
Themost obvious explanation for the superiormortality outcome
with NP-guided therapy is that selected individual patients, based on
plasma BNP/NT-proBNP levels, received appropriately higher doses
of the ACEi and ARB groups of drugs. Although changes across the
studies in doses of the other three groups of drugs (BB, MRA and
loop diuretics) did not differ overall between the two treatment
groups, it is conceivable that alterations in doses of these agents
either upward or downward in individuals within the NP-guided
group, as dictated by BNP/NT-proBNP levels, were more ‘appropri-
ate’ than in clinically guided patients and thereby contributed to the
superior mortality outcome.
Beyond considerations of total mortality, our meta-analysis
showed that NP-guided treatment reduced substantially the
Figure2 Kaplan–Meier survival curves for the primaryendpoint,
overall mortality: (A) total group, (B) below age 75 years (n ¼ 982),
(C) 75 years and above (n ¼ 1018).
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Figure 3 FOREST plot of the primary endpoint, overall mortality, showing unadjusted individual and mean hazards ratios with 95% confidence
intervals for eight studies providing individual patient data and two studies providing aggregate data.
Figure 4 FOREST plot of the secondary endpoint, heart failure hospitalization, showing unadjusted individual and mean hazards ratios with 95%
confidence intervals for nine studies providing individual patient data and two studies providing aggregate data.
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readmission rate forheart failure and forcardiovascular disease.With
regard heart failure, this observation has major financial implications
since hospitalizations dominate the cost ofmanaging this increasingly
common disorder. In the USA, for example, hospitalizations account
for the majority of the US$39 billion spent annually on heart failure
care.25 Accordingly, widespread implementation ofNP-guided therapy
has the potential to reduce considerably the costs of heart failure
care—as indeedwas reported by Laramee et al.26 from studies utiliz-
ing serial measurements of natriuretic peptide levels by a specialist—
except in patients aged .75 years. An added impetus to the
implementation of NP-guided pharmacotherapy in the USA is likely
given that hospitals with high risk-standardized readmission rates
will be subjected to a Medicare reimbursement penalty as of 2013.27
Since any therapeutic plan has the potential to unexpectedly
induce or exacerbate concomitant disorders, it is noteworthy that
therewas no increase in overall hospitalizations and no deterioration
in renal function as gaugedby serumcreatinine levels,withNP-guided
treatment. It seems unlikely, therefore, that unexpected harm results
from the implementation of NP-guided treatment.
Some limitations in our study should be noted. There were differ-
ences in study design particularly regarding BNP/NT-proBNP
targets, although these did not produce heterogeneity in key
results as tested in this meta-analysis. With respect to application
of the NP-guided strategy, use of a single, low target level of BNP
or NT-proBNP may provide more opportunities to up-titrate
therapy. Our meta-analysis, however, cannot provide firm advice
on this matter. Individual patient data were not available from two
published studies;14,15 however, it is unlikely that inclusion of individ-
ual data from these or other unpublished studies would have altered
the overall findings of this meta-analysis. Individual data for adverse
events were not available for analysis from any of the studies.
However, published original reports of each individual study did
not identify any significant difference in adverse events between
study groups. In a subset of the current study cohort, as reported
above, changes in renal function, as measured by plasma creatinine
levels, did not differ between the two study groups.
To date, only NP-guided therapy has been widely tested in rando-
mized controlled studies. However, a wide range of biomarkers
reflecting different aspects of heart failure pathophysiology—includ-
ing markers of renal dysfunction, fibrosis, myocardial necrosis, and
inflammation—provide risk stratification that is incremental to NPs
and could potentially play a role in guiding treatment.28–33 Further
study is certainly needed to evaluate multi-marker strategies to
guide HF therapy.
In summary, this robust individual patient meta-analysis indicates
that for patients aged ,75 years with chronic heart failure most of
whom had impaired left ventricular systolic function, NP-guided
treatment reduced all-cause mortality compared with clinically
guided therapy. This strategy also reduces hospitalizations for heart
failure and cardiovascular disorders, irrespective of age. Therefore,
we propose that NP-guided treatment should be considered in
such patients, although a well-powered, large scale, randomized,
and blinded study which includes adequate numbers of heart failure
patientswith both reduced and preserved EFwould provide reassur-
ance in this regard.
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Table 3 Medications
Baseline Study end
Dose (mean+ SEM) Percent of patients
at target (%)
Dose (mean+ SEM) Percent of patients
at target (%)
Clinical NP Clinical NP Clinical NP Clinical NP
ACEi/ARBa 61+2 64+2 32% 36% 60+2 70+3 34% 41%
Beta-blockera 32+1 38+1 11% 14% 39+2 42+2 19% 19%
Spironolactone (mg) 9.1+0.6 9.5+0.6 26% 26% 9.8+0.6 11.1+0.7 26% 28%
Loop diuretic (mg) 72+3 66+3 – – 66+5 67+5 – –
ACEi/ARB, angiotensin converting enzyme inhibitor or angiotensin type 1 receptor blocker; clinical, clinically guided treatment group; NP, natriuretic peptide guided group.
aACEi/ARB and beta-blocker doses are expressed as percent of target values as defined by guidelines (1) and reported as mean+ standard error of the mean for all subjects within
each treatment group; percent at target, percentage of patients within each treatment group who were at 100% of target dose as defined by guidelines.
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